Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
582 results about "Nanocarriers" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A nanocarrier is nanomaterial being used as a transport module for another substance, such as a drug. Commonly used nanocarriers include micelles, polymers, carbon-based materials, liposomes and other substances. Nanocarriers are currently being studied for their use in drug delivery and their unique characteristics demonstrate potential use in chemotherapy.
Controlled release of immunosuppressants from synthetic nanocarriers
InactiveUS20120301498A1Reduce in quantityReduce percentagePowder deliveryOrganic active ingredientsControlled releaseAntigen
Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.
Owner:SELECTA BIOSCI
Vaccine Nanotechnology
ActiveUS20100233251A1Modulating immune systemEnhance and suppress and direct and immune responseNervous disorderAntipyreticDiseaseNanocarriers
Owner:MASSACHUSETTS INST OF TECH +4
Emulsions and methods of making nanocarriers
This invention relates, in part, to methods of using emulsions for making synthetic nanocarriers and the synthetic nanocarriers formed by such methods.
Owner:SELECTA BIOSCI
Nanocarriers possessing components with different rates of release
InactiveUS20100303850A1Induce and enhance immune responseStrong and long-term humoral immune responsePowder deliveryNervous disorderAntigenNanocarriers
This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise immunomodulatory agents and antigens that are differentially released from the synthetic nanocarriers.
Owner:SELECTA BIOSCI
Targeting of Antigen Presenting Cells with Immunonanotherapeutics
ActiveUS20100129392A1Improve responsePowder deliverySnake antigen ingredientsNanocarriersImmunotherapeutic agent
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and / or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +2
Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
This invention relates to compositions, and related methods, of synthetic nanocarriers that target sites of action in cells, such as antigen presenting cells (APCs), and comprise immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. Also disclosed are compositions and methods relating to synthetic nanocarriers that encapsulate labile immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner.
Owner:SELECTA BIOSCI
Vaccine Nanotechnology
ActiveUS20130236533A1Facilitate acquisitionModulating the immune systemNervous disorderAntipyreticDiseaseNanocarriers
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +3
Multivalent synthetic nanocarrier vaccines
The invention relates, at least in part, to compositions comprising populations of synthetic nanocarriers that comprise different sets of antigens as well as related methods.
Owner:SELECTA BIOSCI
Osmotic mediated release synthetic nanocarriers
InactiveUS20120244222A1Effective amountAntibacterial agentsOrganic active ingredientsNanocarriersChemistry
This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use.
Owner:SELECTA BIOSCI
Synthetic nanocarrier combination vaccines
Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.
Owner:SELECTA BIOSCI
Nanocarrier compositions with uncoupled adjuvant
InactiveUS20110293700A1Rapid and strong systemic inductionAntibacterial agentsPowder deliveryAdjuvantNanocarriers
Disclosed are synthetic nanocarrier compositions with separate adjuvant compositions as well as related methods.
Owner:SELECTA BIOSCI
Immunomodulatory formulations and methods for use thereof
InactiveUS7129222B2Increasing interferon-gammaImprove the situationAntibacterial agentsOrganic active ingredientsNanocarriersImmunomodulations
The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide / microcarrier (IMP / MC) complexes. The IMP / MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a nonbiodegradable microcarrier or nanocarrier.
Owner:DYNAVAX TECH CORP
Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
ActiveUS20120276109A1Reduce frequencyHigh frequencyOrganic active ingredientsPowder deliveryAntigenIMMUNE SUPPRESSANTS
Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.
Owner:SELECTA BIOSCI
Tunable size of nano-active material on nano-support
InactiveUS20110143930A1Limited useful lifeSmall sizeMaterial nanotechnologyMolten spray coatingNanocarriersVapor phase
A method of tuning the size of an nano-active material on a nano-carrier material comprising: providing a starting portion of a carrier material and a starting portion of an active material in a first ratio; adjusting the first ratio, forming a second ratio, thereby tuning the ratio of active material and carrier material; combining the portion of the active material in a vapor phase and the portion of the carrier material in a vapor phase, forming a conglomerate in a vapor phase; and changing the phase of the conglomerate, thereby forming nano-spheres comprising a nano-carrier material decorated with a nano-active material, wherein the size of the nano-active material is dependent upon the second ratio.
Owner:SDC MATERIALS
Immunomodulatory formulations and methods for use thereof
InactiveUS7183111B2Regulate immune responseMore resistant to immunomodulationOrganic active ingredientsNanotechNanocarriersImmunomodulations
The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide / microcarrier (IMP / MC) complexes. The IMP / MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a nonbiodegradable microcarrier or nanocarrier.
Owner:DYNAVAX TECH CORP
Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and / or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
Owner:SELECTA BIOSCI
Immunonanotherapeutics that Provide IgG Humoral Response Without T-Cell Antigen
ActiveUS20100183727A1Improve responseSsRNA viruses negative-senseAntibacterial agentsNanocarriersImmune therapy
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune system response in the form of antibody production, wherein the nanocarriers lack any T cell antigens. In some embodiments, the invention provides nanocarriers that comprise an immunofeature surface, which provides high avidity binding of the nanocarriers to antigen presenting cells. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.
Owner:MASSACHUSETTS INST OF TECH +2
Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
PendingUS20160128987A1Induce immune toleranceDurable immune toleranceBiocideGranular deliveryPolyesterNanocarriers
Disclosed are compositions and methods that provide synthetic nanocarriers that comprise hydrophobic polyester carrier material and rapamycin that is in a stable, super-saturated amount. In some embodiments, the synthetic nanocarriers are also initially sterile filterable. In other embodiments, the rapamycin is present in the synthetic nanocarrier compositions in an amount that is less than 50 weight % rapamycin / hydrophobic polyester carrier material in the composition.
Owner:SELECTA BIOSCI
Tolerogenic synthetic nanocarrier compositions with transplantable graft antigens and methods of use
InactiveUS20120276156A1Eliminate side effectsReduce generationAntipyreticAnalgesicsNanocarriersPlant Antigens
Disclosed are synthetic nanocarrier compositions, and related methods, comprising APC presentable transplant antigens and immunosuppressants that provide tolerogenic immune responses (e.g., a reduction in CD8+ T cell proliferation and / or activity) specific to the APC presentable transplant antigens.
Owner:SELECTA BIOSCI
Control of antibody responses to synthetic nanocarriers
Disclosed are synthetic nanocarrier compositions that comprise B cell antigen for desired antibody production and an off-target response attenuating polymeric coating as well as related methods.
Owner:SELECTA BIOSCI
Dendritic Polymers for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
InactiveUS20080294089A1Increase doseProhibitively expensiveUltrasound therapySurgeryDiseaseNanocarriers
Targeted therapeutic delivery systems comprising specially-designed nanocarriers for intracellular therapeutic delivery, mediated by acoustic energy, for use either in vivo or in vitro are detailed. Nanocarriers comprised substantially of dendritic biopolymers and other species and compounds; are used to treat a variety of diseases in humans and other species, such as cancer, opthalmological, pulmonary, urinary or other pathologies. Methods for preparing the targeted therapeutic delivery systems are also embodied, which comprise processing a solution comprising biopolymers or other species and components, with or without targeting moieties, adding said biopolymers and other compounds to a solution containing one or more therapeutic agents, stabilizing or not stabilizing said nanocarriers, adding one or more contrast agents, resulting in a targeted therapeutic delivery system. Preferred therapeutics for use with the present invention include nucleic acids, proteins, peptides, and other therapeutic macromolecules.
Owner:BIOVALUATION & ANALYSIS
Two-step targeted tumor therapy with prodrug encapsulated in nanocarrier
InactiveUS20110217363A1Reduce activationIncrease targeted activationOrganic active ingredientsPeptide/protein ingredientsNanocarriersTumor therapy
A two-step targeted tumor therapeutic method is described comprising nanocarrier with prodrug encapsulated thereto and prodrug activating enzyme. The enzyme is either encapsulated in nanocarrier, or not encapsulated, or synthesized in the tumor. With the method, the prodrug released from the nanocarrier is activated by the enzyme mainly in the tumor.
Owner:BIONANOX
Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
Disclosed are synthetic nanocarrier compositions and immune checkpoint inhibitor compositions and related methods for administration to a subject.
Owner:SELECTA BIOSCI
Nicotine immunonanotherapeutics
ActiveUS20120027808A1Improve responseEffective amountPowder deliveryNervous disorderNanocarriersT cell
Owner:MASSACHUSETTS INST OF TECH +2
Vaccine Nanotechnology
ActiveUS20130287857A1Facilitate acquisitionModulating the immune systemNervous disorderAntipyreticDiseaseNanocarriers
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +3
Surface-modified hydrophobically modified drug-carried chitosan polymer micelle and method for preparing same
InactiveCN1883708AGood curative effectImprove instabilityPowder deliveryPharmaceutical non-active ingredientsPolymeric surfaceNanocarriers
Disclosed is a surfacely modified hydrophobic Chitosan oligosaccharide polymer drug-loaded colloidal cluster, obtained by grafting chitosan with a average molecular weight of 1.5kD-51kD and aliphatic acid of C10-C22, comprising based on hydrophobic modified Chitosan oligosaccharide polimer colloidal clusters, modifying amidogens or hydroxy groups of Chitosan oligosaccharide molecules on polimer surface with bi-functional small organic moleculers, forming chemical bond bridges between molecules on the surfaces of polymer colloidal clusters,to improve the instability of polymer colloidal cluster diluted, and to imorove the original loose structure of polimer colloidal cluster surfece to form a fine and close net-shaped structure, to decrease a sudden release of drugs, and to control drugs with slow release. The drug-loaded colloidal cluster provided is a nano-carrier with excellent organelle targeting, is applicated in life science field and pharmacy field.
Owner:ZHEJIANG UNIV
Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes
Disclosed herein are nanoparticle, micelle and / or liposome compositions, each comprising a therapeutic agent encapsulated in one or more polymer(s), wherein a vitamin B12 or a derivative thereof is attached to the one or more polymer(s) via a linker group, as well as methods for making and using same.
Owner:ABEONA THERAPEUTICS INC
Tolerogenic synthetic nanocarriers for inducing regulatory b cells
InactiveUS20120276133A1Reduce productionPowder deliveryOrganic active ingredientsEpitopeIMMUNE SUPPRESSANTS
Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and / or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells.
Owner:SELECTA BIOSCI
Tumor environment-induced ligand-expressing nanocarrier system
InactiveUS20050118252A1Minimize interactionIncrease temperatureBiocidePharmaceutical non-active ingredientsNanocarriersNormal cell
Drug delivery compositions for specific delivery of a drug to a tumor are described. These compositions include a core for sequestering the drug and a shell to which a ligand is attached for delivery of a drug to target cells. Since normal cells may also be targeted by the ligand, the compositions embed the ligand in the shell until the localized conditions surrounding the tumor cause the ligand to be displayed on the surface of the shell. One composition exhibits shrinkage of the shell at tumor pH, whereas another composition exhibits extension of the ligand at tumor pH. Still another composition causes the ligand to be exhibited at an elevated temperature.
Owner:UNIV OF UTAH RES FOUND
Magnetic nanomaterial-mediated CRISPR/Cas9 T-cell internal delivery system and preparation method and application thereof
ActiveCN107557393AStrong Magnetic Field ResponseEfficient editingStable introduction of DNANanocarriersMagnetite Nanoparticles
The invention provides a magnetic nanomaterial-mediated CRISPR / Cas9 T-cell internal delivery system and a preparation method and the application thereof. The preparation method comprises the followingsteps: 1) modifying a magnetic nanoparticle cluster with a certain size by using a cationic polymer to obtain a nanocarrier; 2) providing CRISPR / Cas9 system expression plasmids targeting a target gene; 3) co-incubating the nanocarrier obtained in the step 1) and the CRISPR / Cas9 system expression plasmids targeting the target gene to obtain a nanocomposite; 4) under the action of a magnetic field,co-incubating the nanocomposite obtained in the step 3) and a T cell to obtain the magnetic nanomaterial-mediated CRISPR / Cas9 T-cell internal delivery system. According to the invention, a method capable of simply, safely and efficiently editing the target gene in the T cell is provided; the magnetic nanomaterial-mediated CRISPR / Cas9 T-cell internal delivery system has a good application prospectin tumor immunotherapy.
Owner:SHANGHAI INST OF APPLIED PHYSICS - CHINESE ACAD OF SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com